NORTHWEST BIOTHERAPEUTICS INC (NWBO) — SEC Filings

Latest SEC filings for NORTHWEST BIOTHERAPEUTICS INC (NWBO), explained in plain English.

Sentiment Overview: 3 bearish, 23 neutral

Recent Filings (26)

• NW BIO Completes Asset Acquisition/Disposition — 8-K · 2026-04-07T12:30:50-04:00 [neutral] Risk: medium
  On April 7, 2026, NORTHWEST BIOTHERAPEUTICS INC filed an 8-K report detailing the completion of an acquisition or disposition of assets. The period of report fo
• NWBO Seeks 53% Stock Authorization Hike, Board Election at Annual Meeting — DEF 14A · 2025-11-28T00:00:00.000Z [bearish] Risk: high
  Northwest Biotherapeutics, Inc. (NWBO) is holding its Annual Meeting of Stockholders on December 29, 2025, to address several key proposals. The company seeks t
• 8-K Filing — 8-K · 2025-11-20T00:00:00.000Z [neutral]
• NWBO's Mounting Losses Raise Going Concern Doubts Amid Acquisition — 10-Q · 2025-11-14T00:00:00.000Z [bearish] Risk: high
  NORTHWEST BIOTHERAPEUTICS INC reported a net loss of $61.55 million for the nine months ended September 30, 2025, an increase from $55.55 million for the same p
• Northwest Biotherapeutics Enters Material Definitive Agreement — 8-K · 2025-10-31T00:00:00.000Z [neutral] Risk: medium
  On October 27, 2025, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorpor
• Northwest Biotherapeutics Files Material Definitive Agreement — 8-K · 2025-10-30T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics, Inc. reported a material definitive agreement on October 24, 2025. The filing does not disclose specific details of the agreement, th
• Northwest Biotherapeutics Files 8-K: Other Events — 8-K · 2025-10-24T00:00:00.000Z [neutral] Risk: medium
  On October 23, 2025, Northwest Biotherapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant development not
• Northwest Biotherapeutics Files 8-K Report — 8-K · 2025-10-14T00:00:00.000Z [neutral] Risk: low
  On October 9, 2025, Northwest Biotherapeutics, Inc. filed an 8-K report. The filing pertains to 'Other Events' and was submitted on October 14, 2025. No specifi
• NWBO's Cash Up, But Going Concern Doubts Linger Amidst Losses — 10-Q · 2025-08-14T00:00:00.000Z [bearish] Risk: high
  NORTHWEST BIOTHERAPEUTICS INC reported a net loss of $34.7 million for the six months ended June 30, 2025, a slight improvement from the $36.2 million loss in t
• Northwest Biotherapeutics Files Q1 2025 10-Q — 10-Q · 2025-05-15T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business
• Northwest Biotherapeutics Files 2024 10-K — 10-K · 2025-03-31T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics Inc. reported its 2024 fiscal year results, ending December 31, 2024. The company's filing indicates significant financial activities,
• Northwest Biotherapeutics Secures New Loan Agreement — 8-K · 2024-12-26T00:00:00.000Z [neutral] Risk: medium
  On December 19, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, specifically a loan agreement. This agreement creates a dire
• Northwest Biotherapeutics Files Q3 2024 10-Q — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics Inc. reported its Q3 2024 results on November 12, 2024. The company's financial statements for the period ending September 30, 2024, a
• Northwest Biotherapeutics Enters Material Definitive Agreement — 8-K · 2024-11-01T00:00:00.000Z [neutral] Risk: medium
  On October 31, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorpor
• Northwest Biotherapeutics Q2 2024: Assets $69.5M, Cash $550K — 10-Q · 2024-08-09T00:00:00.000Z [neutral] Risk: high
  Northwest Biotherapeutics Inc. reported its Q2 2024 results, with total assets of $69.5 million and cash and cash equivalents of $550,000 as of June 30, 2024. T
• Northwest Biotherapeutics Files 8-K — 8-K · 2024-08-02T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics, Inc. filed an 8-K on August 2, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or
• Northwest Biotherapeutics Files 8-K on Shareholder Votes — 8-K · 2024-07-03T00:00:00.000Z [neutral] Risk: low
  Northwest Biotherapeutics, Inc. filed an 8-K on July 3, 2024, reporting on matters submitted to a vote of security holders as of June 29, 2024. The filing detai
• NW Bio Proxy Statement Filed for June 27th Annual Meeting — DEFA14A · 2024-06-25T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics, Inc. filed a Definitive Proxy Statement (DEFA14A) on June 25, 2024, regarding its upcoming Annual Meeting of Stockholders. The filing
• Northwest Biotherapeutics Files 8-K — 8-K · 2024-06-04T00:00:00.000Z [neutral] Risk: medium
  On May 31, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executiv
• Northwest Biotherapeutics Sets 2024 Annual Meeting for June 29 — DEF 14A · 2024-06-03T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 29, 2024, at 1:30 p.m. local time. The meeting will take place at
• Northwest Biotherapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-10T00:00:00.000Z [neutral] Risk: medium
  NORTHWEST BIOTHERAPEUTICS INC (NWBO) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Northwest Biotherapeutics Inc. filed a 10-Q report for the pe
• Northwest Biotherapeutics Enters Material Definitive Agreement — 8-K · 2024-05-02T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics, Inc. entered into a material definitive agreement on April 26, 2024. This agreement constitutes a direct financial obligation or an o
• Northwest Biotherapeutics Files 10-K/A Amendment — 10-K/A · 2024-04-29T00:00:00.000Z [neutral] Risk: medium
  NORTHWEST BIOTHERAPEUTICS INC (NWBO) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Filing is an Amendment No. 1 to the 10-K for the fis
• Northwest Biotherapeutics Announces Director and Executive Changes — 8-K · 2024-03-22T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics, Inc. announced on March 18, 2024, changes in its board of directors and executive compensation. Specifically, the company reported th
• Northwest Biotherapeutics Reports Officer and Director Changes — 8-K · 2024-03-14T00:00:00.000Z [neutral] Risk: medium
  Northwest Biotherapeutics, Inc. filed an 8-K on March 14, 2024, reporting changes effective March 8, 2024. These changes include the departure of directors or c
• Northwest Biotherapeutics Inc. Files 2023 10-K Report — 10-K · 2024-03-05T00:00:00.000Z [neutral] Risk: high
  NORTHWEST BIOTHERAPEUTICS INC (NWBO) filed a Annual Report (10-K) with the SEC on March 5, 2024. Northwest Biotherapeutics Inc. reported total assets of $106,84